Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Recommendation of “Buy” from Analysts

Trevi Therapeutics, Inc. (NASDAQ:TRVI) has been assigned a consensus recommendation of “Buy” from the twelve brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $22.90.

A number of equities research analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Monday, April 20th. JonesTrading dropped their price objective on shares of Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, March 19th. Morgan Stanley reissued an “overweight” rating and issued a $20.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Finally, D. Boral Capital reissued a “buy” rating and issued a $19.00 price objective on shares of Trevi Therapeutics in a research report on Friday, April 17th.

Trevi Therapeutics Trading Down 1.4%

Shares of NASDAQ:TRVI opened at $13.40 on Thursday. Trevi Therapeutics has a 52 week low of $5.41 and a 52 week high of $16.12. The company’s 50 day moving average is $13.88 and its two-hundred day moving average is $12.46. The company has a market cap of $1.90 billion, a PE ratio of -41.88 and a beta of 1.04.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). As a group, equities research analysts expect that Trevi Therapeutics will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in shares of Trevi Therapeutics by 4.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,346 shares of the company’s stock valued at $195,000 after buying an additional 911 shares during the last quarter. Hilton Head Capital Partners LLC grew its position in shares of Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock valued at $51,000 after buying an additional 1,044 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Trevi Therapeutics by 20.5% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 7,632 shares of the company’s stock valued at $70,000 after buying an additional 1,300 shares during the last quarter. AlphaCentric Advisors LLC grew its position in shares of Trevi Therapeutics by 5.7% in the 1st quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock valued at $286,000 after buying an additional 1,303 shares during the last quarter. Finally, Kennedy Capital Management LLC grew its position in shares of Trevi Therapeutics by 2.4% in the 4th quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock valued at $704,000 after buying an additional 1,336 shares during the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.